Abstract:Neoadjuvant concurrent chemoradiation has become the standard treatment in locally advanced rectal cancer. The target therapy combined with chemoradiation also showed encouraging results. However, there are about 20-30% patients who couldn't get benefit from tumor downstaging due to radio resistance. COX-2 may be involved in tumor radio resistance mechanism. The application of selective COX-2 inhibitor Celecoxib in combination with chemoradiation is appealing in the aspects of overcoming the radio resistance and acting as a potential target therapy. This study is to investigate the COX-2 expression and its significance in locally advanced rectal cancer treated with neoadjuvant concurrent radiation with Capacitabine/Oxaliplatin and Celecoxib. Forty patients with locally advanced rectal cancer were treated in Cancer Hospital, Fudan University from June 2006 to Dec. 2007. All patients were staged IIIB-C based on MRI and endorectal ultrasound examination. All patients underwent pelvic irradiation of 45Gy/25fx/35day. The regimen of concurrent chemotherapy is: Capacitabine 625mg/m2, bid (Mon-Fri.); Oxaliplatin 50mg/m2, weekly and Celecoxib 200mg bid during the whole course. The patients were operated 5-8 weeks followed by concurrent chemoradiation and Celecoxib. Tumor regression grading was evaluated according to the criteria by Rödel. 34 pretreatment biopsies and 24 surgical specimens of COX-2 expression were examined using immunohistochemistry method. Of all specimens, there were 19 patients who had both pretreatment and surgical specimens. Pathological complete response (pCR) was observed in 4 of 40 patients (10%). Downstaging with respect to the tumor stage was observed in 40% patients. The tumor regression grades post neoadjuvant treatment was recorded as: grade 0-1 in 37.5%, grade 2-3 in 50%, grade 4 in 12.5%. COX-2 expression increased in 14 of 19 patients (73.7%) with both pre and post tests from a median of 0% before to 40% after chemoradiation (p = 0.003). COX-2 expression in pretreatment biopsies was not significantly correlated with tumor regression (p = 0.737) and tumor downstaging (p = 0.134). This study showed COX-2 expression in pretreatment biopsies is not associated with tumor regression or tumor downstaging. Elevated expressions of COX-2 post treatment were observed in the majority of tested patients with small samples. More patients with prolonging duration or escalating the dose of celecoxib may need further investigated.

The cancer pain related factors affected by celecoxib together with cetuximab in head and neck squamous cell carcinoma.

[Effect of Selective Cyclooxygenase-2 Inhibitor Celebrex on Expression of Vascular Endothelial Growth Factor (VEGF) in Pancreatic Carcinoma].

Combined Cetuximab and Celecoxib Treatment Exhibits a Synergistic Anticancer Effect on Human Oral Squamous Cell Carcinoma in Vitro and in Vivo

Efficacy and Safety Profile of Celecoxib for Treating Advanced Cancers: A Meta-Analysis of 11 Randomized Clinical Trials

Effect Of Celecoxib Combined With Chemotherapy Drug On Malignant Biological Behaviors Of Gastric Cancer

Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo

Increase of Cyclooxygenase-2 Inhibition with Celecoxib Combined with 5-FU Enhances Tumor Cell Apoptosis and Antitumor Efficacy in a Subcutaneous Implantation Tumor Model of Human Colon Cancer

Comprehensive evaluation of clinical efficacy and safety of celecoxib combined with chemotherapy in management of gastric cancer.

Cyclooxygenase-2 Inhibitor is a Robust Enhancer of Anticancer Agents Against Hepatocellular Carcinoma Multicellular Spheroids

The Role of Cox-2 Expression in Locally Advanced Rectal Cancer Treated with Neoadjuvant Concurrent Radiation with Capecitabine/Oxaliplatin and Celecoxib

ADT-OH Synergistically Enhanced the Antitumor Activity of Celecoxib in Human Colorectal Cancer Cells.

Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study

A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study.

Cetuximab plus other methods in the treatment of patients with head and neck squamous cell carcinomas(HNSCC)

Synergistic inhibitory effect of erlotinib and celecoxib on the growth of cholangiocarcinoma cells

Celecoxib Enhances Radiosensitivity Via Induction of G2-M Phase Arrest and Apoptosis in Nasopharyngeal Carcinoma

Effect of Celecoxib on E-cadherin, VEGF, Microvessel Density and Apoptosis in Gastric Cancer

Celecoxib Induces Cell Apoptosis Coupled with Up-Regulation of the Expression of Vegf by A Mechanism Involving Er Stress in Human Colorectal Cancer Cells

Effect of Taxotere Combination with Celecoxib on Proliferation of NSCLC Cell

Clinical Observation of Cyclooxygenase -2 Inhibitor Celecoxib Combined with Oxycontin in Treatment of Moderate and Severe Cancer Pain

Celecoxib antagonizes the cytotoxicity of oxaliplatin in human esophageal cancer cells by impairing the drug influx